No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NEOG240517C12500
- 0.70
- +0.30+75.00%
15min DelayClose May 14 16:00 ET
0.80High0.65Low
0.65Open0.40Pre Close214 Volume255 Open Interest12.50Strike Price15.47KTurnover116.37%IV2.37%PremiumMay 17, 2024Expiry Date0.59Intrinsic Value100Multiplier3DDays to Expiry0.11Time Value100Contract SizeAmericanOptions Type0.6860Delta0.2505Gamma14.54Leverage Ratio-0.0867Theta0.0007Rho9.98Eff Leverage0.0043Vega
Intraday
- 5D
- 1D
News
Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
Neogen (NEOG) Down 3.6% Since Last Earnings Report: Can It Rebound?
Neogen® to Participate in the Bank of America 2024 Health Care Conference
Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the Bank of America 2024 Health Care Conference in Las Vegas,...
Neogen to Participate in the Bank of America 2024 Health Care Conference
Neogen to Participate in 2024 RBC Capital Markets Global Healthcare Conference
LANSING, Mich., May 7, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 2024 RBC Capital Markets Global Healthcare Conference in New Yor
We Think Neogen (NASDAQ:NEOG) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Comments
Despite Neogen's profitability and revenue growth, its share price drop is surprising and needs further investigation. The company's future earnings are crucial for shareholders. The recent loss is less severe than the 8% annual loss over the last half decade. Clear growth indications are needed before assuming share price stability.
Neogen (NASDAQ:NEOG) Investors Are Sitting on a Loss of 58% If They Invested Three Years AgoThe drop in stock price is in line with the decline in Neogen's earnings, which is expected under normal market conditions. The recent insider buying may suggest some confidence in the company's future prospects despite the slump in financial performance.
1
$MorphoSys(MOR.US$initiated at overweight by Wells Fargo, announced target price at $17.00.
$Guess(GES.US$initiated at neutral by UBS, announced targe price at $22.00.
$West Pharmaceutical Services(WST.US$was upgraded by Bank of America Securities from neutral to buy, increased target price from $390.00 to $405.00.
$AutoZone(AZO.US$was upgraded by UBS from neutral to buy, increased target price from $2800.00 to $2900.00.
$RPC Inc(RES.US$was downgr...
$Guess(GES.US$initiated at neutral by UBS, announced targe price at $22.00.
$West Pharmaceutical Services(WST.US$was upgraded by Bank of America Securities from neutral to buy, increased target price from $390.00 to $405.00.
$AutoZone(AZO.US$was upgraded by UBS from neutral to buy, increased target price from $2800.00 to $2900.00.
$RPC Inc(RES.US$was downgr...
20
11
QUICK SCALP 18 $NEOG — STOCK & OPTION PLAY
ALERT ON: $18.06
ON THE WATCH: $18.19
FIRST SIGNED OF MORE UPTREND - $18.24
NEED IT TO BREAK OVER: $18.39
key indicator for MORE uptrend $18.58
confirmation uptrend - $18.65
mini breakout - $18.76
Prepare for bigger breakout: $18.91. $Neogen(NEOG.US$
ALERT ON: $18.06
ON THE WATCH: $18.19
FIRST SIGNED OF MORE UPTREND - $18.24
NEED IT TO BREAK OVER: $18.39
key indicator for MORE uptrend $18.58
confirmation uptrend - $18.65
mini breakout - $18.76
Prepare for bigger breakout: $18.91. $Neogen(NEOG.US$
$Neogen(NEOG.US$ “ELISA-based diagnostic testing solutions for rapid allergen detection” allergy sensitivity, no problem! Neogen has your back! (https://www.neogen.com/solutions/allergens/)
Read more